Inventor · disambiguated record
Michael Croft
Also filed as: CROFT MICHAEL · CROFT MICHAEL D · CROFT MICHAEL S
16 granted patents·12 pending applications·303 citations·filing 2002–2023
95Inventor score
Files withJOLLA INST ALLERGY IMMUNOLOG7CROFT MICHAEL5LA JOLLA INST ALLERGY & IMMUNOLOGY5KATO SHINICHIRO2KYOWA KIRIN CO LTD2
Top patents by PatentIndex Score
28 records- 0196US8551477B1Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying sameCROFT MICHAEL·Filed 2011·Granted Oct 8, 2013·43 cites·20 claims
- 0295US8956615B1Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying sameJOLLA INST ALLERGY IMMUNOLOG·Filed 2013·Granted Feb 17, 2015·23 cites·20 claims
- 0395US8283450B2Human monoclonal antibody human CD134 (OX40) and methods of making and using sameKATO SHINICHIRO·Filed 2006·Granted Oct 9, 2012·47 cites·11 claims
- 0495US8101175B1Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying sameCROFT MICHAEL·Filed 2008·Granted Jan 24, 2012·33 cites·26 claims
- 0595US7291331B1Methods of treating OX40 medicated recall immune responsesJOLLA INST ALLERGY IMMUNOLOG·Filed 2003·Granted Nov 6, 2007·63 cites·54 claims
- 0694US9873744B1Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying sameLA JOLLA INST ALLERGY & IMMUNOLOGY·Filed 2015·Granted Jan 23, 2018·8 cites·20 claims
- 0794US7807156B1Methods of treating OX40 mediated recall immune responsesJOLLA INST ALLERGY IMMUNOLOG·Filed 2007·Granted Oct 5, 2010·26 cites·24 claims
- 0894US7531170B1Methods of treating OX40 mediated recall immune responses and agents useful for identifying sameJOLLA INST ALLERGY IMMUNOLOG·Filed 2006·Granted May 12, 2009·24 cites·40 claims
- 0989US9475878B2Human monoclonal antibody human CD134 (OX40) and methods of making and using sameKATO SHINICHIRO·Filed 2012·Granted Oct 25, 2016·12 cites·12 claims
- 1088US11192953B2Human monoclonal antibody human CD134 (OX40) and methods of making and using sameKYOWA KIRIN CO LTD·Filed 2018·Granted Dec 7, 2021·2 cites·25 claims
- 1183US9969810B2Human monoclonal antibody human CD134 (OX40) and methods of making and using sameKYOWA HAKKO KIRIN CO LTD·Filed 2016·Granted May 15, 2018·3 cites·18 claims
- 1282US9838502B2Systems and methods for RWD app store based collaborative enterprise information managementCROFT MICHAEL D·Filed 2015·Granted Dec 5, 2017·7 cites·24 claims
- 1379US12319741B2Human monoclonal antibody human CD134 (OX40) and methods of making and using sameKYOWA KIRIN CO LTD·Filed 2021·Granted Jun 3, 2025·0 cites·17 claims
- 1478US8349320B2Compositions and methods for modulating responses mediated or associated with BTLA activityJOLLA INST ALLERGY IMMUNOLOG·Filed 2009·Granted Jan 8, 2013·9 cites·17 claims
- 1573US9301994B2LIGHT inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatmentCROFT MICHAEL·Filed 2011·Granted Apr 5, 2016·3 cites·21 claims
- 1670US2023406947A1Light inhibitors for scleroderma and skin fibrotic disease treatmentLA JOLLA INST ALLERGY & IMMUNOLOGY·Filed 2023·Application pending·0 cites
- 1761US2005171798A1Method and system for minimizing the risk of leasing trucksFiled 2004·Application pending·0 cites
- 1861US2021179725A1Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatmentLA JOLLA INST ALLERGY & IMMUNOLOGY·Filed 2020·Application pending·0 cites
- 1959US2009136427A1LIGHT Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease TreatmentJOLLA INST ALLERGY IMMUNOLOG·Filed 2008·Application pending·0 cites
- 2053US10106619B2Virus vaccination and treatment methods with OX40 agonist compositionsCROFT MICHAEL·Filed 2007·Granted Oct 23, 2018·0 cites·16 claims
- 2150US2017058037A1Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatmentLA JOLLA INST ALLERGY & IMMUNOLOGY·Filed 2016·Application pending·0 cites
- 2248US2023159649A1Methods and combinations for dual targeting of tnf family membersLA JOLLA INST FOR IMMUNOLOGY·Filed 2021·Application pending·0 cites
- 2348US2018016345A1Light inhibitors for scleroderma and skin fibrotic disease treatmentLA JOLLA INST ALLERGY & IMMUNOLOGY·Filed 2016·Application pending·0 cites
- 2446US2007167405A1Galectins -1 and -4 in tumor developmentHUFLEJT MARGARET E·Filed 2006·Application pending·0 cites
- 2541US2003109464A1Galectins -1 and -4 in tumor developmentFiled 2002·Application pending·0 cites
- 2640US2009311280A1Novel tnf receptor regulatory domainJOLLA INST ALLERGY IMMUNOLOG·Filed 2005·Application pending·0 cites
- 2734US2018319889A1Method and medicament for treating airway and/or lung diseasesLA JOLLA INST FOR ALLERGY & IMMUNOLOGY·Filed 2016·Application pending·0 cites
- 2833US2014234320A1Modulators of 4-1bb and immune responsesCROFT MICHAEL·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael Croft files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →